Cellular therapy · BLA
Lenmeldy (Atidarsagene autotemcel) NDC 83222-0200
Atidarsagene autotemcel 11800000 1/1 · Suspension · Intravenous · Orchard Therapeutics (Europe) Ltd
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 83222-0200-1 | 83222020001 | 1 SUSPENSION in 1 BAG (83222-0200-1)Marketed from Apr 26, 2024 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Lenmeldy
- Generic name (nonproprietary)
- atidarsagene autotemcel
- Active ingredients
- Atidarsagene autotemcel — 11800000 1/1
- Dosage form
- Suspension
- Route
- Intravenous
- Labeler
- Orchard Therapeutics (Europe) LtdNDC labeler code 83222
- Product type
- Cellular therapy
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 125758
- Marketing start
- Listing expires
- Identifiers
- Product ID 83222-0200_5474a8af-7dd9-3e6a-e063-6294a90a8de2SPL ID 5474a8af-7dd9-3e6a-e063-6294a90a8de2SPL set ID b3e307a7-561b-43b6-a784-9cb1dcfc5196RxCUI 2677920, 2677926UNII EPP8G99QG4
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N483222020001followed by a unit qualifier and the quantityPackage 83222-0200-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
LENMELDY is indicated for the treatment of children with pre-symptomatic late infantile (PSLI), pre-symptomatic early juvenile (PSEJ) or early symptomatic early juvenile (ESEJ) metachromatic leukodystrophy (MLD). LENMELDY is an autologous hematopoietic stem cell-based gene therapyindicated for the treatment of children with pre-symptomatic late infantile (PSLI), pre-symptomatic early juvenile (PSEJ) or early symptomatic early juvenile (ESEJ) metachromatic leukodystrophy (MLD).
Excerpt only. Read the full label for complete information.
About NDC 83222-0200
- What is NDC 83222-0200?
- 83222-0200 is the product NDC for Lenmeldy (atidarsagene autotemcel), Atidarsagene autotemcel 11800000 1/1 suspension, listed with the FDA by Orchard Therapeutics (Europe) Ltd. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Lenmeldy (Atidarsagene autotemcel).
- What is the active ingredient?
- Atidarsagene autotemcel.
- Who is the labeler?
- Orchard Therapeutics (Europe) Ltd, NDC labeler code 83222. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Lenmeldy?
- None: this is the only finished product listed under this name.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.